Assertio Therapeutics (ASRT) Reports In-Line Q3 EPS; Raises Outlook
Tweet Send to a Friend
Assertio Therapeutics (NASDAQ: ASRT) reported Q3 EPS of $0.24, in-line with the analyst estimate of $0.24. Revenue for the quarter ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
